Drugs / Neutrophil Activation Probe (NAP)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02804854 | Dec 2016 → Jul 2022 | lung disorder | University of Edinburgh | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neutrophil Activation Probe (NAP) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02804854 ↗ |
| Known as | NAP | “Delivery of NAP by direct pulmonary administration followed by fibreoptic confocal microendoscopy.” NCT02804854 ↗ |
| Modality | Diagnostic / imaging agent | “optical molecular imaging” NCT02804854 ↗ |
| Route | Other | “direct pulmonary administration” NCT02804854 ↗ |